Dear Germaine,

  Dasatinib is working great for you!  You are only 10%Ph+ and you had
not achieved remission on Gleevec.  That is great news.

  Rob is very right, chromosomal abnormalities in cells not having the
Ph chromosome are not so worrisome.  From articles I have read, doctors
say that these additional chromosomal abnormalities can be present with
the Ph chromosome but when the Ph chromosome percentage goes down due
to the targeted approach of Gleevec/Dasatinib, this can give a
selective advantage to cells with abnormal chromosomes to grow.

  There have been many studies on chromosome abnormalities that crop up
on Gleevec patients.  It is called Ph negative clonal evolution since
these abnormalities occur in cells not having the Ph chromosome.  The
incidence with Gleevec is around 10% so not very common.  Many of the
patients who have these abnormalities have seen them disappear over
time, they are transient and disappear with further therapy.  What
doctors do, however, is monitor these patients by doing periodic BMAs
and the reason for that is that a small percentage of patients having
these abnormalities, especially monosomy 7, have developed different
diseases like myelodysplastic syndrome (MDS) and acute leukemia.
Monosomy 7 is one chromosome 7 missing.  Trisomy 8 is an extra copy of
chromosome 8.

  I personally know two patients who had more than your percentage of
Trisomy 8 and with therapy, these percentages are going down and for
one patient, it is completely gone.  There is no reason for Dasatinib
not to behave similarly, it is a stronger targeted therapy than
Gleevec.  Since Dasatinib is very new, articles on the drug are just
coming out.  I have been helping the BMS trial patients in our clinic
and quite a few of them had trisomy 8 and it disappeared on therapy.

  Below, I give the most recent Ph negative clonal evolution article
which happens to be from Canada.

Here is a
study of 141 Canadian patients during Gleevec therapy. The incidence of
patients who developed chromosomal abnormalities other than the Ph
chromosome is
only 8.7% in 3 years follow-up so it is relatively rare as also seen
from
worldwide studies. The Canadian patients who developed the
abnormalities, 7 had
either monosomy 7 (loss of chromosome 7) or trisomy 8 (extra copy of
chromosome
8), 1 had a loss of X chromosome and chromosome 22 and 1 had a
translocation
between chromosomes 12 and 16. 2 patients presented with same
chromosomal
abnormality in Ph negative and positive cells. The emergence of the
abnormalities occurred median 13.3 months after the start of Gleevec.
This may
follow from the hypothesis that small amounts of these abnormalities
may be
present at start of therapy and after Gleevec reduces the phillies,
these
abnormalities give a selective growth to cells with the abnormal
chromosomes
which proliferate. Patients who took Gleevec 1 year after diagnosis or
less had
more risk of developing these abnormalities. None of the patients who
developed
the abnormalities developed myelodysplasia. And there was no difference
in
event-free survival on Gleevec in these patients compared to those who
did not
have the abnormalities. So, the authors conclude that even though the
development of chromosomal abnormalities are rare, they may occur more
on
Gleevec therapy than on other CML therapies but do not confer a worse
prognosis.

I have given the article below.  Here are two things you can now do:

1.  It does seem to me that your doctors may not have many cases of
trisomy 8.  OHSU has a database for Gleevec patients having chromosomal
abnormalities.  Maybe, this is an opportune time to consult with Dr.
Brian Druker and have his feedback on your options.  OHSU keeps a
database on patients who develop chromosomal abnormalities on Gleevec.
I know you are very much wanting to consult there, please do convince
your Mom that now may be the time.  You want the best medical advice
from a CML expert and not be rushed into a BMT.

2.  Your doctors can ask Bristol-Myers-Squibb about the incidence of
chromosomal abnormalities on Dasatinib and what is recommended.

Germaine, I am looking at the broader picture, you are responding well
to Dasatinib, achieving remission with a drug when Gleevec did not do
that job.  Odds are that the chromosomal abnormalities will disappear
but do take the medical opinion of OHSU experts on this, they have a
broad experience on Gleevec and Dasatinib is a stronger inhibitor.

Avail of all medical expert opinions on drug therapy and only then
consult for transplant.  Seems to me you are doing very well on
Dasatinib.

Warm Wishes,
Anjana
caregiver to Roy

: Cancer Genet Cytogenet. 2006 Oct 1;170(1):16-23. Links
Philadelphia-negative clonal hematopoiesis following imatinib therapy
in
patients with chronic myeloid leukemia: a report of nine cases and
analysis of
predictive factors.
a.. Lin Y,
b.. Bruyere H,
c.. Horsman DE,
d.. Pantzar T,
e.. Barnett MJ,
f.. Hogge DE,
g.. Nevill TJ,
h.. Nantel SH,
i.. Sutherland HJ,
j.. Toze CL,
k.. Shepherd JD,
l.. Lavoie JC,
m.. Song KW,
n.. Smith CA,
o.. Forrest DL.
The Leukemia/BMT Program of British Columbia, the Division of
Hematology, 950
West 10th Avenue, Room 3300, Vancouver, British Columbia V5Z 4E3,
Canada.

There are increasing reports of Philadelphia-negative (Ph-negative)
clonal
hematopoiesis developing among patients with chronic myeloid leukemia
(CML)
treated with imatinib mesylate (IM). To establish the incidence and
significance
of these chromosomal abnormalities, we analyzed data on 141 consecutive
patients
with CML treated with IM at the British Columbia Cancer Agency and
Vancouver
General Hospital from 1999 to 2004. The cumulative incidence of
developing a
Ph-negative clone three years from the start of IM was 8.7% at a median
of 13.3
months. The Ph-negative clonal abnormalities included monosomy 7 and/or
trisomy
8 (seven patients), monosomy for chromosomes X and 22 (one patient),
and a
(12;16) translocation (one patient). Two of the patients presented with
the same
chromosomal abnormality in both Ph-negative and Ph-positive cells. None
of the
Ph-negative clonal abnormalities was associated with myelodysplasia. In
a
multivariate analysis, an interval from diagnosis to initiation of IM
of 1 year
or less was associated with an increased risk of developing a
Ph-negative clone
(relative risk = 20.2; P = 0.025). There was no difference, however, in
event-free survival between patients who did and did not develop
Ph-negative
clones. Therefore, while the development of Ph-negative clonal
hematopoiesis in
patients with CML treated with IM is uncommon, it appears to be more
frequent
than that previously seen with IFN, but it does not seem to confer a
worse
prognosis.


--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------

You received this message because you are subscribed to the Google Groups 
"CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---

Reply via email to